Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (2473)	7/21/1999 11:52:00 PM
From: Jim Roof	Respond to of 10293

Bill, I find it interesting that your argument hinges on the opinion that Hextend is nothing more than an equivalent to Hespan and other generic heatstarches in saline. My interest in your argument is even more piqued by the fact that Abbott Labs just sent a sales force of 150 to argue the case for Hextend, NOT to those who use the generics or Hespan BUT to those you use crystalloids and albumin. Your opinion, which you are entitled to, that Hextend's market potential is no greater than the market for Hespan/equivalents seems to come under some pressure now that Abbott is making their first sales thrust directly into the albumin and crystalloid market. That is why BTIM has rallied for the past few days and that is why your short at 20 hopefully has been covered. You can claim that BTIM has hoodwinked a small investor and that small investor will not have the data nor the resources to negate your claims but Abbott is another matter. They seem to think that Hextend will address a much larger market and have, like me, put their money/resources on the line to that end. Take care, Jim